Vaxxas Opens World-Class Manufacturing Facility To Produce Proprietary Needle-Free Vaccine Patch For Late-Stage Clinical Trials and First Commercial Products

CAMBRIDGE, Mass. & BRISBANE, Australia--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform technology, today announced the opening of its

Related Keywords

Australia ,Cambridge ,Cambridgeshire ,United Kingdom ,Brisbane ,Queensland ,United States ,Australian ,Kathryn Morris ,David Hoey ,Amy Miller ,Development Authority ,European Medicines Agency ,Oneventures Innovation Fund ,Economic Development Queensland ,Manufacturing Initiative ,Coalition For Epidemic Preparedness Innovations ,University Of Queensland ,Melinda Gates Foundation ,Drug Administration ,World Health Organization ,Australian Government Innovation Investment Fund ,Yates Network ,Australian Therapeutic Goods Administration ,United States Biomedical Advanced Research ,Queensland Government ,Good Manufacturing Practice ,Vaxxas Biomedical Facility ,Australian Government ,Modern Manufacturing Initiative ,Deputy Premier ,State Development ,Local Government ,Minister Assisting ,Paralympic Games Infrastructure ,Steven Miles ,Palaszczuk Government ,Development Queensland ,Premier Steven Miles ,Chief Executive Officer David Hoey ,Queensland State ,Australian Federal Governments ,United States Food ,Epidemic Preparedness Innovations ,Brandon Capital Partners ,Brandon Biocatalyst ,Healthcare Ventures ,Innovation Investment Fund ,